Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multi-site, Randomized, Open-label Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of BNT327 at Two Dose Levels in Combination With Chemotherapeutic Agents as First- and Second-line Treatment in Triple-negative Breast Cancer

NCT06449222 is registered in ClinicalTrials.gov with BioNTech SE as lead sponsor.

NCT NCT06449222
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06449222 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multi-site, Randomized, Open-label Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of BNT327 at Two Dose Levels in Combination With Chemotherapeutic Agents as First- and Second-line Treatment in Triple-negative Breast Cancer
Lead sponsor
BioNTech SE
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 26, 2024
Completion date
June 30, 2029
Enrollment
83 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced breast cancer, metastatic triple negative breast cancers, triple negative breast cancer